Membrane Separation Technology on Pharmaceutical Wastewater by Using MBR (Membrane Bioreactor)

This study demonstrated the feasibility of implementing of MBR in pharmaceutical wastewater independently, and concluded different applications of MBR in industries. Membrane bioreactor (MBR) technology was a new wastewater treatment technology with a combination of membrane separation technology and biological treatment technology, which had unique advantages on pharmaceutical wastewater treatment. The modified membrane rector design provided a significantly lower concentration of NH3-N, Phosphorous, Total Nitrogen and COD around the membranes, and subsequently a more sustainable membrane performance due to much lower overall fouling rates. In this paper, the classification and structure of biological waste water treatment by using MBR technology were summed up along with some examples of MBR in industrial wastewater treatment, which was emphatically analyzed and discussed. Finally, the prospect of MBR in industrial wastewater treatment was described. The industrial wastewater was a high-strength wastewater which had characteristics of complicated constituents, high organics concentration, highly toxic.

Next 10 years in pharmaceutical manufacturing information technology

Today the ASEAN Pharmaceutical manufacturing companies are still focusing on their local countries,with the exception of a fewlarge regionals who are already and increasingly looking and capable to export to the outside markets such as Europe.This means that the majority of companies producing medicinal products to higher regulatory standards have less international experience/exposure in handling the GMP requirements demanded by PIC/s[1].In addition most of their processes are manual with legacy practices,and mostly the data and controls are in paper with a very high amount of data made with pen and paper on numerous human reviews of documentation mainly to assess the data is complete but not for accuracy of the data at the time that action could be taken—data integrity on paper has been shownto be highly questionable.

Research on the Function of Government Fund Support in Pharmaceutical Industry Technology Innovation

Pharmaceutical technology innovation process needs a lot of human, material and financial support, so the government must give full play to its financial support function. Specifically, the government should improve the fund investment mechanism of the pharmaceutical industry, improve the financial investment management system of pharmaceutical technology innovation, strengthen the function and mechanism of the capital market, improve the risk investment system, focus on cultivating a good credit environment, and increase the support of national policy-based financial institutions. Through direct investment, financial subsidies, tax incentives and low-interest financing and other means, vigorously promote the improvement of pharmaceutical innovation capacity.

Discussion on the Choice of Technology Innovation Strategy of Chinese Pharmaceutical Enterprises

Over the past few years,China’s extensive domestic power has been continually enhanced,and the economy,science,and technology are constantly evolving.Thus,people’s living standards have also been significantly improved.In contemporary culture,individuals are increasingly demanding high-quality,safe lives and,on the one side,all regular necessities such as life-related,drug safety is a must attach huge significance.However,the state’s investment in medical care is not particularly large due to the late start of China’s medical industry.As a result,the pharmaceutical equipment of pharmaceutical companies in China still has many problems and there are potential hidden dangers in drug safety.The pharmaceutical companies in China are innovating on this basis.In technology,research and discussion,many problems appear and related solutions are proposed.

Online pharmaceutical process analysis of Chinese medicine using a miniature mass spectrometer: Extraction of active ingredients as an example

The automation of traditional Chinese medicine(TCM)pharmaceuticals has driven the development of process analysis from offline to online.Most of common online process analytical technologies are based on spectroscopy,making the identification and quantification of specific ingredients still a challenge.Herein,we developed a quality control(QC)system for monitoring TCM pharmaceuticals based on paper spray ionization miniature mass spectrometry(mini-MS).It enabled real-time online qualitative and quantitative detection of target ingredients in herbal extracts using mini-MS without chromatographic separation for the first time.Dynamic changes of alkaloids in Aconiti Lateralis Radix Praeparata(Fuzi)during decoction were used as examples,and the scientific principle of Fuzi compatibility was also investigated.Finally,the system was verified to work stably at the hourly level for pilot-scale extraction.This mini-MS based online analytical system is expected to be further developed for QC applications in a wider range of pharmaceutical processes.

Process analytical technologies and self-optimization algorithms in automated pharmaceutical continuous manufacturing

The pharmaceutical industry is now paying increased attention to continuous manufacturing.While the revolution to continuous and automated manufacturing is deepening in most of the top pharma companies in the world,the advancement of automated pharmaceutical continuous manufacturing in China is relatively slow due to some key challenges including the lack of knowledge on the related technologies and shortage of qualified personnels.In this review,emphasis is given to two of the crucial technologies in automated pharmaceutical continuous manufacturing,i.e.,process analytical technology(PAT)and self-optimizing algorithm.Research work published in recent 5 years employing advanced PAT tools and self-optimization algorithms is introduced,which represents the great progress that has been made in automated pharmaceutical continuous manufacturing.

Corporate Social Responsibility in Health Technology Industry Prior and during the Covid-19 Pandemic, in Greece

Corporate Social Responsibility (CSR) activities have been revealed as an emerging managerial tool and research field. The socioeconomic impact of the COVID-19 pandemic has prompted several companies to take on CSR initiatives. The objective of this study was to investigate CSR initiatives implemented in companies specializing in pharmaceutical and biomedical products as well as medical equipment, prior and during the COVID-19 pandemic. A cross-sectional study was conducted in companies of the Hellenic Association of Pharmaceutical Companies (SFEE), the Panhellenic Association of Pharmaceutical Industry (PEF) and the Association of Health-Research and Biotechnology Industry (SEIV). A self-administered questionnaire was distributed to a total of 112 companies. Descriptive and multivariate statistical analyses were performed using SPSS 25.0. Levels of significance were two-tailed and statistical significance was set at p = 0.05. The final sample consisted of 74 companies with a response rate of 77.7%. Among them 62.2% were multinational and 37.8% national companies. Some companies provided pharmaceuticals (40.5%), medical equipment and biotechnology products (32.4%) and others were specializing in both categories (27.1%). A percentage equal to 89.2% stated that they implemented CSR activities, out of which 75.7% carried out COVID-19 related initiatives, such as in public health (37.7%), societal issues (27.2%), environment (19.9%), etc. Approximately 50% increased their CSR activities during the pandemic. Moreover, the majority of companies devoted ≤30% of their total CSR budget against the pandemic. The higher a company’s turnover, the higher CSR activities performance. Pharmaceutical and biomedical companies in Greece implemented CSR actions, prior and during the pandemic. Companies contributed to handle the effects of health crisis through CSR Covid-19 related activities, which differentiated according to company’s culture and wealth. It is important that authorities should reward companies carrying out CSR initiatives, given that they positively contribute to the societal recovery by financially supporting the health care sector and the overall economy.

本科分流培养模式下药物发现中关键技术新课程的构建

培养一流人才、服务国家战略是“双一流”建设的重要指导思想。面向国家对药学高层次人才的需求,中山大学药学院对高年级本科生实施药物化学、药理学、药剂学三大方向的分流培养。目的是强化学生对学科发展前沿的把握,提升学生对药学基础知识的综合运用以及解决问题的能力,激发学生的创新能力。以药物发现中的关键技术课程为例,文章介绍在药物化学方向下建立配套课程的设计思路及教学内容、教学方法与教学成效,为药学精英人才培养提供新思路。

乡村振兴背景下高职药品生产技术专业研学实践教育研究——以桂林师范高等专科学校为例

全面推进乡村振兴,是以习近平同志为核心的党中央从中国式现代化建设全局出发、顺应亿万农民对美好生活的向往作出的重大决策,旨在实现农村经济的发展、农民生活水平的提高和农村社会的全面进步。乡村振兴背景下的研学实践教育研究,旨在探索研学实践教育与乡村振兴之间的关系,为乡村振兴提供理论支持和实践指导。文章以桂林师范高等专科学校为例,提出通过校乡企“三联动”构建药品生产技术专业研学实践教育,传播中医药文化,提高学生的专业能力。

制药类专业教学中培养绿色制药能力的设计与实践——以《制药工艺学》课程为例

在绿色化学视野下,绿色制药思维是制药类人才的必备素质。以制药类人才培养方案为准绳,以制药工艺学课程为载体,在绿色制药能力培养方面进行了设计。教学中在课程思政融入、教学内容优化、研教结合、指导性自学、以赛促学、多学科融合等方面做了基于培养绿色制药能力的探索和实践。

《药房自动化与信息技术标准》制订与解析

医疗机构药学部门以患者为中心的药事管理与药学服务能力的提升,离不开自动化与信息化。《医疗机构药事管理与药学服务》第4-4部分:药房自动化与信息技术标准是中国医院协会团体标准之一,对医疗机构自动化建设的基本要求、自动化硬件设备建设、智慧化信息平台建设、质量管理与持续改进4个方面32个关键要素进行了规范,可用于指导各级各类医疗机构对药房自动化设备与信息平台的选型与优化。该文介绍了《药房自动化与信息技术标准》的构建方法和内容,以加深同行对该标准的理解,促进该标准的落地执行。进一步推动医疗机构药学服务现代化、信息化与智慧化,提高整体医疗药事管理与服务的质量和效率。

基于严重指数法对药物制剂技术课程思政建设成效初探

目的课程思政是教育全面育人重要环节,探索建立课程思政建设成效评价的导向因素。方法以药物制剂技术课程为对象,采用严重指数法对本课程思政的建设效果进行定量分析,剖析影响其课程思政建设效果的关键6个影响因素,通过严重指数指标计算各因素的严重指数值,并进行排序后提出有效建议。结果学生和教师各自最严重的影响因素分别为“思政教育内容喜闻乐见表现力关联性”和“思政教育与教学内容关联性”,其严重指数分别为95.0%和85.0%。结论基于制药行业和健康中国的大思政元素,实施思政教育能力培训计划,顶层设计医药知识与课程思政元素融合方案,强化专业知识技能与思政元素的不可分割性。

“双高计划”背景下教学创新团队建设研究

教学创新团队建设是职业教育教学质量提升的重要举措,同时也是高职院校内涵发展、质量发展、可持续发展的重要抓手。文章以国家职业教育药品生产技术教师教学创新团队建设为实践载体,聚焦现代制药产业高端人才培养目标要求,以习近平新时代中国特色社会主义思想为指引,以团队教师技术技能积累与协同创新能力提升为主线,以校企协同工作机制和跨界培养机制为保障,打造校企合作、专兼结合的高水平结构化教学创新团队,为药品生产技术专业技术技能人才培养提供强有力的师资保障,进而形成职业教育教师教学创新团队建设的“范式”。

一流课程建设背景下中药制药工艺学课程的建设与探讨

中药制药工艺学作为中药制药专业的专业核心课程,在中药制剂开发和生产中极为重要。在一流本科课程建设背景下,本文结合当前中药制药工艺学课程建设中存在的问题,从突出中医药思维培养、优化教学内容、加大综合性实验课程开设、强化讨论式教学、思政引领—制药工程与设备相结合的教学模式等方面进行中药制药工艺学课程建设探讨,有望为中药制药工艺学课程建设提供参考。

药物制剂技术课程教学改革与实施--以丸剂制备技术项目为例

以“岗课赛证”融通为基础,对药物制剂技术课程进行教学改革,从教学内容、教学模式、教学资源、评价体系等方面探索教学改革的路径。以丸剂制备技术项目为例,从学情分析、教学目标、教学过程、课程思政等方面阐述项目教学实施过程。通过教学改革,提升了教学质量,改善了教学效果,为其他相关课程教学改革提供参考。

管理层薪酬差距对医药制造企业技术创新影响

企业为了保持在市场上长期稳定和市场竞争力,创新成为必不可少的一环,优化企业薪酬结构有利于激发企业活力并进一步促进企业技术创新。本文选取中国2010—2021年A股上市公司中医药制造企业的数据,采用多种回归模型对管理层内外部薪酬差距对企业技术创新的影响进行实证。研究发现,对于医药制造企业,管理层内外部薪酬差距对企业技术创新具有正向作用。对于模型的选取,管理层内部薪酬差距数据的右偏特性使其对技术创新绩效的影响使用Tobit模型更为妥当;对于管理层外部薪酬差距,双重差分模型和Logit模型结合使用更为适合,Logit模型可以从整体上分析,而双重差分模型可以将政策影响纳入其中。医药制造企业可以适当提高关键管理层的薪酬水平,拉大管理层内外薪酬差距,激发管理者工作积极性,提高企业技术创新动力与效率。

化学计量学指导原则在我国制药行业中的需求分析

目的:了解和把握我国制药行业的现状和实际需求,为《中国药典》通则“化学计量学指导原则”的建立提供依据。方法:以网络问卷的形式对制药行业从业人员化学计量学相关背景和需求进行调研。结果:我国制药行业从业人员对化学计量学指导原则具有一定期望和需求,但人才储备情况不容乐观。结论:《中国药典》通则“化学计量学指导原则”的制订极为迫切,其作为法定依据指导分析实践活动中的数据质量控制、分析方法的建立及分析方法的验证,以保障多变量分析方法的科学性和分析结果的可靠性,这将有利于推动我国制药水平的提高。

中药工业智能制造转型模式及监管问题探讨

中药制药工业质量控制水平的提升需要以科技创新为引领,以先进制药工程技术为支撑。智能制造融合了先进制造技术与信息技术,已经成为提高制造业质量与效益的先进生产方式。本研究聚焦中药工业实施智能制造重大战略工程,根据中药产品质量及其制造流程的特点,结合中药制药工业面临的管控问题以及智能制造技术特征,提出中药产业发展智能制造的转型方向,核心包括由基于经验的控制向以数据为驱动力的控制转型、产品检验向过程管控转型、分散向集成转型,以及药品制造向药品全生命周期服务转型等领域的突破。总结近年来中药标杆性企业在智能制造技术研究方面取得的成果以及产业转化进展,讨论中药产业在智能制造转型过程中面临的监管问题,以期为中药工业实施智能制造项目的系统架构规划与技术路线设计提供参考。

我国医药制造业研发投入状况及其影响的实证研究

目的 分析我国医药制造业研发投入现况,探索其对科技创新产出的影响,进而为卫生健康科技创新投入提出相关建议。方法 收集2009年1月至2020年12月我国内地31个省、自治区、直辖市(不含港、澳、台)医药制造业研究与试验发展(R&D)支出、R&D活动企业数、R&D人员数、R&D人员全时当量、年人均卫生费用、每千人卫生人员数、人均受教育年限和有效发明专利数等数据,运用描述性统计分析医药制造业研发投入的变化趋势、区域差距,建立面板数据计量经济学模型,分析医药制造业研发投入对有效发明专利数的影响作用。结果 2009—2020年,我国医药制造业R&D经费投入总量从154.5亿元上升到906.5亿元,总体增长486.7%,年均增长17.5%。面板计量经济学模型结果显示,创新企业个数、医药制造业研发投入和年人均卫生费用对有效发明专利数的影响有统计学意义,具体为:每增加1个R&D活动企业,有效发明专利增加3.884个;R&D投入每增加1万元,有效发明专利增加0.004个;年人均卫生费用每增加1元,有效发明专利增加0.081个。结论 2009—2020年,我国医药制造业研发投入对科技创新作用的推动作用具有积极意义,建议未来进一步加强对医药创新企业的支持,继续增加医药制造业研发投入,并促进健康服务业发展,以加快我国卫生健康科技创新。